Show simple item record

dc.contributor.authorPonnusamy, Suriyan
dc.contributor.authorHe, Yali
dc.contributor.authorHwang, Dong-Jin
dc.contributor.authorThiyagarajan, Thirumagal
dc.contributor.authorHoutman, Rene
dc.contributor.authorBocharova, Vera
dc.contributor.authorSumpter, Bobby G.
dc.contributor.authorFernandez, Elias
dc.contributor.authorJohnson, Daniel
dc.contributor.authorDu, Ziyun
dc.contributor.authorPfeffer, Lawrence M.
dc.contributor.authorGetzenberg, Robert H.
dc.contributor.authorMcEwan, Iain J.
dc.contributor.authorMiller, Duane D.
dc.contributor.authorNarayanan, Ramesh
dc.date.accessioned2020-09-02T23:06:44Z
dc.date.available2020-09-02T23:06:44Z
dc.date.issued2019-11
dc.identifier.citationPonnusamy , S , He , Y , Hwang , D-J , Thiyagarajan , T , Houtman , R , Bocharova , V , Sumpter , B G , Fernandez , E , Johnson , D , Du , Z , Pfeffer , L M , Getzenberg , R H , McEwan , I J , Miller , D D & Narayanan , R 2019 , ' Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer ' , Clinical Cancer Research , vol. 25 , no. 22 , pp. 6764-6780 . https://doi.org/10.1158/1078-0432.CCR-19-1458en
dc.identifier.issn1078-0432
dc.identifier.otherPURE: 146002560
dc.identifier.otherPURE UUID: 58dca3ef-6c27-4472-aaaf-5883270fbfc8
dc.identifier.otherPubMed: 31481513
dc.identifier.otherMendeley: ff2ee6b2-d612-3083-bd9b-c5945063a762
dc.identifier.otherScopus: 85074356016
dc.identifier.otherWOS: 000497334300024
dc.identifier.urihttps://hdl.handle.net/2164/15067
dc.descriptionAcknowledgement. BGS acknowledges work performed at the Center for Nanophase Materials Sciences, a DOE Office of Science User Facility. VB acknowledges Laboratory Directed Research and Development program of Oak Ridge National Laboratory, managed by UTBattelle, LLC, for the U.S. Department of Energy.en
dc.format.extent17
dc.language.isoeng
dc.relation.ispartofClinical Cancer Researchen
dc.rightsThis manuscript has been accepted for publication in Clinical Cancer Research, which is published by the American Association for Cancer Research.en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectprostate canceren
dc.subjectCastration-Resistant Prostate Cancer (CRPC)en
dc.subjectandrogen receptor (AR)en
dc.subjectAR degrader (SARD)en
dc.subjectcoactivatoren
dc.subjectenzalutamide-resistant prostate canceren
dc.subjectPHOSPHORYLATIONen
dc.subjectCYP17A1 INHIBITORen
dc.subjectSPLICE VARIANTen
dc.subjectANTITUMOR-ACTIVITYen
dc.subjectDIFFERENTIAL REGULATIONen
dc.subjectBREAST-CANCERen
dc.subjectANTIANDROGENen
dc.subjectGENEen
dc.subjectINCREASED SURVIVALen
dc.subjectABIRATERONEen
dc.subjectRC0254 Neoplasms. Tumors. Oncology (including Cancer)en
dc.subjectOncologyen
dc.subjectCancer Researchen
dc.subjectSupplementary Dataen
dc.subject.lccRC0254en
dc.titleOrally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Canceren
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Institute of Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Clinical Medicineen
dc.description.statusPeer revieweden
dc.description.versionPostprinten
dc.identifier.doihttps://doi.org/10.1158/1078-0432.CCR-19-1458
dc.date.embargoedUntil2020-09-03
dc.identifier.urlhttp://www.mendeley.com/research/orallybioavailable-androgen-receptor-degrader-potential-nextgeneration-therapeutic-enzalutamideresisen
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85074356016&partnerID=8YFLogxKen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record